Analysis of Zydus Cadila's corporate history, corporate relationships, biosimilars development pipeline, and Datamonitor's evaluation of the company's strategy and key strengths, weaknesses, opportunities and threats.
Description
INTRODUCTION
This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's biosimilars portfolio, including analysis of key product profiles, examining key drivers and resistors to development, market sizing, specifics of development such as clinical trials (where available) for each key biosimilar molecule in development.
FEATURES AND BENEFITS
Strategic insight into the key strategies that have shaped the company's progress and/or will define its outlook going forward.
Provides an indication of how biosimilars fit into the wider company context, and a history of deals & alliances.
HIGHLIGHTS
Zydus Cadila has a wide variety of biosimilars in its portfolio covering a number of indications, including five copy-biologics that are available in India, with a further 12 candidates in development, two of which are in clinical trials. The remaining 10 are at various stages of preclinical development, four of which are monoclonal antibodies.
YOUR KEY QUESTIONS ANSWERED
Evaluate key products in Zydus's broad biosimilars portfolio covering a number of indications
See how partnerships will prove crucial for international product launches
Table of Contents
Table of Contents
ABOUT THIS REPORT
Chapter structure
Strategic insight
Product analysis
Operating performance
Company introduction
Data sourcing
Analyst consensus
PharmaVitae Explorer database
EXECUTIVE SUMMARY
Zydus Cadila's biosimilars overview
Zydus Cadila biosimilars SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
Zydus Cadila biosimilars infrastructure
STRATEGIC INSIGHT
Zydus Cadila utilizes simple biologic products to gain market experience
A strong market position gives Zydus Cadila an advantage to expand its biosimilars portfolio globally…
…but international market entry will require partners
KEY PRODUCTS
Overview
Zydus Cadila biosimilar portfolio
EPO (erythropoietin)
Overview
Erythropoietin market size
Key competitors
Zydus Cadila biosimilar development
G-CSF and PEG G-CSF (filgrastim and pegfilgrastim)
Overview
Filgrastim and pegfilgrastim market size
Key competitors
IFN-A 2B and PEG IFN-A 2B (interferon alpha-2b and peginterferon alpha-2b)
Overview
Interferon alpha and peginterferon market size
Key competitors
Zydus Cadila biosimilar development
IFN-B 1B (interferon beta-1b)
Overview
Interferon beta market sizing
Key competitors
Zydus Cadila's biosimilar development
Teriparatide (teriparatide)
Overview
teriparatide market size
Key competitors
Other pipeline copy-biologic/biosimilar candidates
OPERATING PERFORMANCE
Zydus Cadila's financial performance over 2005-11
Operating costs and profit analysis, 2004-10
CORPORATE STRUCTURE
Background
Company structure
Deals and alliances
Recent developments
APPENDIX
References
Datamonitor reports
Biologic definitions
Exchange rates
TABLES
Table: Zydus Cadila - manufacturing and development metrics
Figure: Zydus Cadila - revenues by segment and geographic region, 2010-11
Zydus Cadila: Biosimilars Company Analysis published by Datamonitor in July 6, 2012. This report consists of Pages: 44 and the price starts from US $ 3800.
